Italy studies limiting puberty blockers for transsexual minors. Triptorelin, a drug originally intended for the treatment of prostate cancer, was used in Italy until 2018 to block puberty in trans minors only when families fully covered the price.
In 2019, the National Health System began to cover the full cost of the drug, despite the numerous criticisms it received, especially from the most conservative Catholic groups. The Italian Society of Psychoanalysis has written to the Government to express its “great concern” and “strong perplexity” over the use of puberty blockers.